Top Ten Tips for Caregivers
Director of Communications Mary Garland shares these top ten tips for caregivers for this GIST journey.
Spokane GISTers Gather for Food & Sharing Along the Journey
Five GISTers and four caregivers attend the luncheon at Europa Restaurant and Bakery. Besides a great meal, attendees were able to meet each other and share our journeys through their GIST journeys.
Steve Pontell – Newest Board Member
The Life Raft Group announces Steve Pontell, Esq. as the newest addition to our Board of Directors.
Management of Adults with SDH-Deficient GISTs
Dr. Andrew Blakely, Program Director, Surgical Oncology Research Fellowship, National Cancer Institute, National Institutes of Health, shares how his team works with adult SDH-deficient GIST patients.
Building a Network of Rare Specialists
Margo Shoup is a doctor on a mission. She moved from the Chicago area to Connecticut almost a year ago and has been the catalyst behind the creation of specialized disease teams targeting cancer care in a health system that covers an extensive area from western Connecticut up into the Hudson Valley of New York State.
Making New Connections in NJ
Earlier this month, members of the LRG staff were invited to the Rutgers Cancer Institute of New Jersey by sarcoma specialist Dr. Roman Groisberg.
Partnership for Survival – Treating the Rarest of the Rare
Our Rare Disease Day offering is a whitepaper titled 'Partnership for Survival – Treating the Rarest of the Rare' detailing how a collaboration with the NIH has become a model for other advocacy groups and researchers.
Patient of the Month for February: Richard Schoenbohm
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Richard Schoenbohm shares his story.
Priority Review Granted for Ripretinib
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
NCI Mentions LRG as Component in Development of Ayvakit
In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.